Rocket Lab's Backlog Is $2.36 Billion -- More Than Double Its 2026 Revenue -- and the Stock Still Fell 38% This Month. Here's the Disconnect.

Source The Motley Fool

Key Points

  • After a heroic mid-year runup prompted by SpaceX's splashy IPO, Rocket Lab shares have struggled.

  • The company has postponed the inaugural launch of a new rocket design several times in recent months.

  • More and more investors may be quietly concerned about the actual amount of potential net upside from here.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

By most measures, Rocket Lab (NASDAQ: RKLB) shares should be well higher.

As of July, its backlog stood at $2.36 billion, or nearly 2.5 times this year's anticipated revenue of $959 million (which is up 59% versus last year's top line). The space-launch company has completed several more successful flights of its Electron rocket too, proving it's up to the task of putting smaller satellites into orbit.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

And yet the stock's on pace to lose 16% of its value in October, leaving it 16% below 2025's closing price despite a fantastic midyear run-up. What gives? This action is a reminder that young story stocks, driven more by narrative than by numbers, can only do so much for so long.

Reality's making it easier to undermine

Simply put, Rocket Lab's business is cost-effectively putting satellites into space. Thanks to new technologies and materials, a handful of corporations can now offer what only government-run space agencies once could.

As of this month, Rocket Lab's partly reusable Electron rocket has been flown 98 times. This company also offers satellite tech, as well as satellite assembly services. This technology arm accounts for about two-thirds of its business, and it nearly doubled year over year in Q2.

It's all good news, so why is the stock's performance poor?

It would be naïve to pretend that repeated delays in the inaugural launch of its medium-lift Neutron rocket, capable of lifting more than 14 tons, aren't weighing on investors' minds. Initially expected to fly as early as 2024, developmental delays -- several of them just within the past few months -- have repeatedly pushed this date back.

Indeed, the company announced in mid-October that it won't be happening this year after all, but instead, sometime next year. Investors responded with the predictable sell-off.

There may be more to the matter than Neutron's developmental setbacks, though. Even if unconsciously, it's arguable that the market's realizes this persistently unprofitable company's stock is priced at 40 times this year's expected sales. Not earnings. Sales -- a detail that wasn't a concern just a few months ago.

A worried investor is staring at a laptop. screen.

Image source: Getty Images.

Whatever growth is in store, it's going to take a long, long time for RKLB's current price to make any sense. Its far bigger rival, Space Exploration Technologies (NASDAQ: SPCX), continues to refine its medium-lift launch capabilities in the meantime.

Handle with care

As outrageous as the revenue-based valuation seems compared to the S&P 500's trailing price/sales ratio of around 3.6, this sort of dynamic isn't unheard of for such businesses. It's kind of common, in fact, with new story stocks that attract lots of attention for reasons other than the potential profits that may or may not be on the table.

Those bullish underpinnings don't last forever without proper support, though. Eventually, investors start thinking about the numbers.

There's the rub with RKLB here and now. There's still some story for speculators to latch on to here. There are just fewer and fewer story-driven speculators left to latch on. That doesn't necessarily mean a story stock suddenly stops performing cold turkey. As time marches on, however, it certainly becomes more difficult to do so.

This doesn't mean Rocket Lab is strictly off-limits to interested investors. Just make sure you know what you're buying into and why it might still not behave like a more typical stock.

Missed AI’s "Act 1"? Act 2 Could Be 14x Bigger

Most investors think they missed the AI boat because they didn't buy Nvidia in 2005.

But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout, a massive technology build-out that Google’s CEO says could be more profound than fire or electricity.

While everyone watches the chip designers, one "backbone" company provides the critical technology that Nvidia and AMD literally cannot function without. We’ve detailed this under-the-radar player in our new AI Playbook.

Continue »

James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Anthropic files for a $2 trillion IPO — the $80.7 billion loss is the decoy, the $450 billion compute bill is the riskAnthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
Author  Irene Q.
Oct 27, Tue
Anthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
placeholder
Brent's $115 front month sits $4.6 above January — the $14 spread to WTI is the supply-risk premiumDecember Brent trades at $115.29 while January is $110.71, a $4.58 backwardation. The December Brent-WTI spread is $14.2, versus a $3-5 normal. That gap, not the headline, is where the Middle East supply risk is priced. Here is what the curve says, why the December contract's expiry on October 30 will mechanically cut the headline by $4.6, and the 108.81 neckline that decides the next move.
Author  Irene Q.
Oct 28, Wed
December Brent trades at $115.29 while January is $110.71, a $4.58 backwardation. The December Brent-WTI spread is $14.2, versus a $3-5 normal. That gap, not the headline, is where the Middle East supply risk is priced. Here is what the curve says, why the December contract's expiry on October 30 will mechanically cut the headline by $4.6, and the 108.81 neckline that decides the next move.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - October 29, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 29, 2026. Read on for the details.
Author  Mitrade
Oct 29, Thu
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 29, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - October 30, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 30, 2026. Read on for the details.
Author  Mitrade
Oct 30, Fri
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 30, 2026. Read on for the details.
placeholder
US GDP grew 3.4% and core PCE held at 3.1% — December is now a hike trade, not a cut tradeUS Q3 GDP rose 3.4%, above the 3.1% estimate, while September headline PCE hit 3.6% and core held at 3.1%. December hike odds are near 90%; inventories, AI capex and energy explain why.
Author  Irene Q.
Oct 30, Fri
US Q3 GDP rose 3.4%, above the 3.1% estimate, while September headline PCE hit 3.6% and core held at 3.1%. December hike odds are near 90%; inventories, AI capex and energy explain why.
goTop
quote